Search results
Results from the WOW.Com Content Network
Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease. [1] [3] [4] [5]The most common side effects include stomatitis (mouth sores of the lips, mouth, and throat), low levels of platelets, white blood cells, and red blood cells, and febrile neutropenia (fever and low white blood cell count), consistent with ...
Casgevy will cost $2.2 million for the one-time treatment, Vertex said in a regulatory filing, while Lyfgenia will cost $3.1 million, bluebird said in a news release.
December 8, 2023 at 1:19 PM. The Food and Drug Administration on Friday approved a powerful treatment for sickle cell disease, a devastating illness that affects more than 100,000 Americans, the ...
In separate clinical trials, both the treatments helped reduce painful episodes in patients with the disease, with 29 of 31 patients receiving Casgevy, and 28 of 32 patients on Lyfgenia showing ...
Lyfgenia: In December 2023, the company received FDA approval of lovo-cel for the treatment of sickle cell disease in patients 12 years and older who have a history of vaso-occlusive events, with an announced wholesale acquisition cost of $3.1 million. [23] Lyfgenia carries a boxed warning of potential risk for hematologic malignancy (blood ...
Alipogene tiparvovec was expected to cost around $1.6 million per treatment in 2012, [206] revised to $1 million in 2015, [207] making it the most expensive medicine in the world at the time. [208] As of 2016 [update] , only the patients treated in clinical trials and a patient who paid the full price for treatment have received the drug.
While Lyfgenia utilizes a gene therapy technique that’s been used in patients with various genetic disorders since the 2010s, Dr. Punam Malik, director of the Sickle Cell Center at Cincinnati ...
The Congressional Budget Office (CBO) estimated that the health insurance premium for single coverage would be $6,400 and family coverage would be $15,500 in 2016. The annual rate of increase in premiums has generally slowed after 2000, as part of the trend of lower annual healthcare cost increases. [38]